Study S000195

A Trial Investigating the Influence of Omeprazole on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02249871
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 54
Start: 2014-09-24
Primary completion: 2015-04-01
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:semaglutide; DRUG:Omeprazole
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2013-005513-12; OTHER:U1111-1151-5077

Registered primary outcomes

Area under the semaglutide plasma concentration time curve [From time 0 to 24 hours after the 10th daily dose]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011209	Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Overgaard RV, Clinical pharmacokinetics	2021	Other trial	PMID 33969456 DOI	cites ClinicalTrials.gov:NCT02249871; registry reference DERIVED:33969456
R0019667	A randomized study investigating the effect of omeprazole on the pharmacokinetics of oral semaglutide. Bækdal TA, Expert opinion on drug metabolism & toxicology	2018	Randomized trial	PMID 29897249 DOI	registry reference RESULT:29897249